Metabolic Dysfunction-Associated Steatotic Liver Disease: Pathogenetic Links to Cardiovascular Risk

被引:0
|
作者
Ionescu, Vlad Alexandru [1 ,2 ]
Gheorghe, Gina [1 ,2 ]
Bacalbasa, Nicolae [3 ,4 ]
Diaconu, Camelia Cristina [1 ,2 ,5 ]
机构
[1] Univ Med & Pharm Carol Davila Bucharest, Fac Med, Bucharest 050474, Romania
[2] Clin Emergency Hosp Bucharest, Internal Med Dept, Bucharest 105402, Romania
[3] Fundeni Clin Inst, Ctr Digest Dis & Liver Transplantat, Dept Visceral Surg, Bucharest 022328, Romania
[4] Univ Med & Pharm Carol Davila, Dept Surg, Bucharest 050474, Romania
[5] Acad Romanian Scientists, Bucharest 050085, Romania
关键词
MASLD; cardiovascular risk; pathophysiology; myocardial ischemia; heart failure; atrial fibrillation; NONALCOHOLIC FATTY LIVER; EPICARDIAL ADIPOSE-TISSUE; AORTIC-VALVE SCLEROSIS; SUPERFAMILY MEMBER 2; INSULIN-RESISTANCE; HEPATIC STEATOSIS; ATRIAL-FIBRILLATION; GENERAL-POPULATION; GENETIC-VARIATION; OXIDATIVE STRESS;
D O I
10.3390/biom15020163
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD) is correlated with an increased cardiovascular risk, independent of other traditional risk factors. The mechanisms underlying this pathogenic link are complex yet remain incompletely elucidated. Among these, the most significant are visceral adiposity, low-grade inflammation and oxidative stress, endothelial dysfunction, prothrombotic status, insulin resistance, dyslipidemia and postprandial hyperlipemia, gut dysbiosis, and genetic mutations. Cardiovascular diseases are the leading cause of death in patients with MASLD. These patients have an increased incidence of coronary artery disease, carotid artery disease, structural and functional cardiac abnormalities, and valvulopathies, as well as arrhythmias and cardiac conduction disorders. In this review, we present the latest data on the association between MASLD and cardiovascular risk, focusing on the pathogenic mechanisms that explain the correlation between these two pathologies. Given the high rates of cardiovascular morbidity and mortality among patients with MASLD, we consider it imperative to raise awareness of the risks associated with this condition within the general population. Further research is essential to clarify the mechanisms underlying the increased cardiovascular risk linked to MASLD. This understanding may facilitate the identification of new diagnostic and prognostic biomarkers for these patients, as well as novel therapeutic targets.
引用
收藏
页数:22
相关论文
共 50 条
  • [31] From metabolic dysfunction-associated fatty liver disease to metabolic dysfunction-associated steatotic liver disease: Controversy and consensus
    Chen, Li
    WORLD JOURNAL OF HEPATOLOGY, 2023, 15 (12) : 1253 - 1257
  • [32] Metabolic dysfunction-associated steatotic liver disease and low handgrip strength are independently associated with a higher risk for cardiovascular disease
    Kim, Seung Up
    Lee, Jae Seung
    Lee, Hye Won
    Kim, Mi Na
    Kim, Beom Kyung
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    JOURNAL OF HEPATOLOGY, 2024, 80 : S498 - S498
  • [33] Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
    Moon, Joon Ho
    Jeong, Seogsong
    Jang, Heejoon
    Koo, Bo Kyung
    Kim, Won
    ECLINICALMEDICINE, 2023, 65
  • [34] Metabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study
    Peng, Yu
    Wang, Peng
    Liu, Fubin
    Wang, Xixuan
    Si, Changyu
    Gong, Jianxiao
    Zhou, Huijun
    Gu, Jiale
    Qin, Ailing
    Song, Weijie
    Song, Fangfang
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 1940 - 1949
  • [35] Increased risk of cancers in metabolic dysfunction-associated steatotic liver disease and MetALD
    Park, Yewan
    Jung, Jooyi
    Kim, Gi-Ae
    JOURNAL OF HEPATOLOGY, 2024, 80 : S468 - S468
  • [36] Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective
    Eskridge, Wayne
    Cryer, Donna R.
    Schattenberg, Joern M.
    Gastaldelli, Amalia
    Malhi, Harmeet
    Allen, Alina M.
    Noureddin, Mazen
    Sanyal, Arun J.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (19)
  • [37] Predictors of Atherosclerotic Cardiovascular Disease Events in Patients with Metabolic Dysfunction-associated Steatotic Liver Disease
    Kawanaka, Miwa
    Nishino, Ken
    Kawada, Mayuko
    Ishii, Katsunori
    Tanikawa, Tomohiro
    Urata, Noriiyo
    Suehiro, Mitsuhiko
    Haruma, Ken
    Kawamoto, Hirofumi
    INTERNAL MEDICINE, 2024,
  • [38] Psychosocial risks in metabolic dysfunction-associated steatotic liver disease
    Astrom, Hanne
    Takami Lageborn, Christine
    Hagstrom, Hannes
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025, 19 (03) : 273 - 290
  • [39] Drivers of cardiovascular disease in metabolic dysfunction-associated steatotic liver disease: the threats of oxidative stress
    Minetti, Erika T.
    Hamburg, Naomi M.
    Matsui, Reiko
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11
  • [40] Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Targher, Giovanni
    CURRENT OBESITY REPORTS, 2024, 13 (02) : 242 - 255